Key Facts

Zydus Cadila is a global healthcare provider and one of the top five pharma companies in India. The company was founded by Late Mr Ramanbhai B. Patel in 1952 and went on to become the second largest pharma company in the early 1990s.

In 1995, the group restructured its operations and now operates as Cadila Healthcare Ltd., under the aegis of the Zydus group. The company spearheaded by Mr Pankaj R. Patel, Chairman and Managing Director has posted revenues of Rs. 5200 crores in FY12. The group had posted a turnover of Rs. 4600 crores in FY 11, making it a billion dollar company.

The group was declared the 'Emerging Company of the Year' by the Economic Times Awards for Corporate Excellence 2010.

The group has proven expertise in manufacturing and marketing different dosage forms such as solid dosage forms, injectables, metered dose inhalers, dry powder inhalers, transdermal patches, suppositories and oncology formulations.

It has a wide therapy coverage through three multi-therapy divisions and 16 speciality divisions. The divisions are spearheaded by some of the stalwarts in the field of pharma marketing.

A dedicated field force of 4000 reaches out to super specialists, specialists, surgeons, physicians and the rural markets.

The group has a strong presence in the cardiovascular, gastrointestinal, womens healthcare segments, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences,

dermatology and nephrology segments. The group has several brands that feature amongst the top 300 pharmaceutical brands in India. The group has a globally compliant manufacturing infrastructure comprising nine state-of-the-art facilities which support product launches not just in India but also in the regulated markets of U.S., Europe and Latin America. Four of the groups facilities including the formulation manufacturing plant at Moraiya, and API plants at Ankleshwar and Dabhasa near Vadodara are approved by the USFDA. More than 1000 professionals spearhead the groups research programme.

Over 375 scientists are working on new molecular entity research at the Zydus Research Centre. The group has 12 INDs in various stages of clinical trials.

Zydus Cadila is a partner of choice for several global pharma majors such as Abbott, Boehringer Ingelheim, Bayer Pharma, Madaus AG, Nycomed, Hospira to name a few.

Zydus Wellness Ltd., which spearheads the group's presence in the consumer and wellness segment was recently listed amongst Asia's 200 Best under a Billion companies by Forbes.

One of the most reputed pharma companies globally, Zydus Cadila aims to be a leading global healthcare provider with a robust product pipeline. Stepping beyond the billion, the group aspires to achieve sales of over $3bn by 2015 and be a research-driven pharmaceutical company by 2020.